Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DWTX NASDAQ:ENTX NASDAQ:HOTH NASDAQ:MGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDWTXDogwood Therapeutics$1.72+1.8%$2.18$1.28▼$9.50$57.45M1.6878,510 shs15,893 shsENTXEntera Bio$1.21+3.3%$1.22$0.91▼$3.22$56.88M1.54206,814 shs23,988 shsHOTHHoth Therapeutics$0.69+4.7%$0.81$0.49▼$2.12$13.20M0.571.98 million shs152,227 shsMGXMetagenomi$1.35-0.4%$1.45$1.25▼$3.95$50.64M0.63229,387 shs87,906 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDWTXDogwood Therapeutics+2.42%+15.75%-15.08%-44.04%-62.94%ENTXEntera Bio-10.00%+6.36%+1.74%-19.31%-45.58%HOTHHoth Therapeutics-1.49%-9.71%+28.00%-30.52%-30.71%MGXMetagenomi-4.26%-2.88%-2.17%-14.01%-10.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDWTXDogwood Therapeutics$1.72+1.8%$2.18$1.28▼$9.50$57.45M1.6878,510 shs15,893 shsENTXEntera Bio$1.21+3.3%$1.22$0.91▼$3.22$56.88M1.54206,814 shs23,988 shsHOTHHoth Therapeutics$0.69+4.7%$0.81$0.49▼$2.12$13.20M0.571.98 million shs152,227 shsMGXMetagenomi$1.35-0.4%$1.45$1.25▼$3.95$50.64M0.63229,387 shs87,906 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDWTXDogwood Therapeutics+2.42%+15.75%-15.08%-44.04%-62.94%ENTXEntera Bio-10.00%+6.36%+1.74%-19.31%-45.58%HOTHHoth Therapeutics-1.49%-9.71%+28.00%-30.52%-30.71%MGXMetagenomi-4.26%-2.88%-2.17%-14.01%-10.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDWTXDogwood Therapeutics 2.00Hold$12.00597.67% UpsideENTXEntera Bio 2.00Hold$9.00644.42% UpsideHOTHHoth Therapeutics 2.00Hold$5.00623.59% UpsideMGXMetagenomi 2.80Moderate Buy$9.00569.14% UpsideCurrent Analyst Ratings BreakdownLatest HOTH, ENTX, MGX, and DWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026MGXMetagenomi Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$12.00 ➝ $9.005/1/2026MGXMetagenomi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/27/2026DWTXDogwood Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026DWTXDogwood Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/27/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.004/24/2026HOTHHoth Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026ENTXEntera Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/25/2026HOTHHoth Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.003/4/2026HOTHHoth Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.002/20/2026DWTXDogwood Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDWTXDogwood TherapeuticsN/AN/AN/AN/A$2.33 per shareN/AENTXEntera Bio$40K1,409.09N/AN/A$0.29 per share4.17HOTHHoth TherapeuticsN/AN/AN/AN/A$0.40 per shareN/AMGXMetagenomi$25.21M2.01N/AN/A$4.22 per share0.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDWTXDogwood Therapeutics-$34.26M-$18.90N/AN/AN/AN/A-2,027.44%-31.29%5/14/2026 (Estimated)ENTXEntera Bio-$11.44M-$0.27N/AN/AN/AN/A-77.13%-66.26%N/AHOTHHoth Therapeutics-$12.47M-$0.90N/AN/AN/AN/A-139.84%-126.88%6/3/2026 (Estimated)MGXMetagenomi-$87.87M-$2.37N/AN/AN/A-348.54%-47.14%-33.82%N/ALatest HOTH, ENTX, MGX, and DWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/AHOTHHoth Therapeutics-$0.1378N/AN/AN/AN/AN/A5/14/2026Q1 2026DWTXDogwood Therapeutics-$0.22N/AN/AN/AN/AN/A5/11/2026Q1 2026MGXMetagenomi-$0.57-$0.61-$0.04-$0.61$5.90 million$1.25 million5/8/2026Q1 2026ENTXEntera Bio-$0.08-$0.07+$0.01$0.07N/AN/A3/27/2026Q4 2025ENTXEntera Bio-$0.09-$0.07+$0.02$0.07N/AN/A3/27/2026Q4 2025HOTHHoth Therapeutics-$0.1031-$0.16-$0.0569-$0.16N/AN/A3/18/2026Q4 2025DWTXDogwood Therapeutics-$1.22-$0.26+$0.96-$0.26N/AN/A3/5/2026Q4 2025MGXMetagenomi-$0.58-$0.60-$0.02-$0.60$7.33 million$3.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDWTXDogwood TherapeuticsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDWTXDogwood TherapeuticsN/A2.762.76ENTXEntera BioN/A6.946.94HOTHHoth TherapeuticsN/A4.724.72MGXMetagenomiN/A7.227.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDWTXDogwood Therapeutics9.05%ENTXEntera Bio14.11%HOTHHoth Therapeutics7.08%MGXMetagenomiN/AInsider OwnershipCompanyInsider OwnershipDWTXDogwood Therapeutics0.20%ENTXEntera Bio10.38%HOTHHoth Therapeutics6.92%MGXMetagenomi17.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDWTXDogwood Therapeutics533.40 million33.34 millionN/AENTXEntera Bio2046.62 million41.78 millionOptionableHOTHHoth Therapeutics419.13 million17.80 millionNot OptionableMGXMetagenomi23637.65 million30.95 millionN/AHOTH, ENTX, MGX, and DWTX HeadlinesRecent News About These CompaniesMetagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results3 hours ago | markets.businessinsider.comMetagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue EstimatesMay 11 at 9:06 PM | zacks.comMetagenomi (MGX) to Release Earnings on TuesdayMay 10 at 3:34 AM | americanbankingnews.comMetagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 9 at 6:37 AM | marketbeat.comMetagenomi (MGX) Projected to Post Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing ...April 16, 2026 | markets.businessinsider.comMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing EfficiencyApril 16, 2026 | globenewswire.comMetagenomi, Inc. (NASDAQ:MGX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 14, 2026 | marketbeat.comDid Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?April 13, 2026 | prnewswire.comMetagenomi Therapeutics: Q4 Earnings SnapshotMarch 5, 2026 | sfgate.comMetagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue EstimatesMarch 5, 2026 | zacks.comMetagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial ResultsMarch 5, 2026 | globenewswire.comMetagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference TranscriptMarch 4, 2026 | seekingalpha.comMetagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare ConferenceFebruary 23, 2026 | globenewswire.comMGX Resources Limited (MTGRY) Q2 2026 Earnings Call Prepared Remarks TranscriptFebruary 18, 2026 | seekingalpha.comIs Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans?February 12, 2026 | finance.yahoo.comMGX Resources Limited (MTGRY) Shareholder/Analyst Call Prepared Remarks TranscriptJanuary 22, 2026 | seekingalpha.comMetagenomi, Inc.: Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate OutlookJanuary 12, 2026 | finanznachrichten.deMetagenomi Therapeutics Rebrands to Emphasize Therapeutic FocusJanuary 12, 2026 | tipranks.comMetagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate OutlookJanuary 12, 2026 | globenewswire.comMetagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature ConferenceDecember 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOTH, ENTX, MGX, and DWTX Company DescriptionsDogwood Therapeutics NASDAQ:DWTX$1.72 +0.03 (+1.78%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.Entera Bio NASDAQ:ENTX$1.21 +0.04 (+3.33%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Hoth Therapeutics NASDAQ:HOTH$0.69 +0.03 (+4.68%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Metagenomi NASDAQ:MGX$1.34 -0.01 (-0.37%) As of 11:02 AM Eastern This is a fair market value price provided by Massive. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
